Stocks on the Move - Bristol-Myers Squibb, (NYSE:BMY), Amgen, (NASDAQ:AMGN)

Stocks on the Move - Bristol-Myers Squibb, (NYSE:BMY), Amgen, (NASDAQ:AMGN)

Bristol-Myers Squibb Company (NYSE:BMY) is now showing 71.1% EPS growth this Quarter. Jolley Asset Management LLC increased its position in shares of Bristol-Myers Squibb by 4.0% in the second quarter.

Currently Bristol-Myers Squibb Company (BMY) captured an average recommendation of " Overweight " from analysts. This is a proprietary weighted technical model built by Capital Market Labs (CML). During the last six months the stock slipped -18.39%. Finally, Chevy Chase Trust Holdings Inc. raised its stake in Bristol-Myers Squibb by 1.1% in the second quarter.

Following Earnings result, share price were DOWN 15 times out of last 27 Qtrs. Also published the news titled: "Bristol-Myers Squibb Co: THIS Will Influence Where BMY Stock Goes Next" on October 25, 2016. BMY's value Change from Open was at -0.19% with a Gap of -0.12%.

The stock's price switched up 5.38% 20-Days Simple Moving Average, added 6.49% from 50-Days Simple Moving Average and fell -10.47% from 200 Days Simple Moving Average.

Bristol-Myers Squibb Company's (BMY) stock price ended its day with a loss of -0.32% and finalized at the price of $56.55. The quarterly report of Bristol-Myers Squibb Company (NYSE:BMY) can be made public close to 2017-01-26. Bristol-Myers Squibb's valuation multiple has followed the industry's overall trend for the last five years. The company had revenue of $4.83 billion for the quarter, compared to the consensus estimate of $4.76 billion. However a year ago for the same quarter the company has reported $0.38 EPS.

The high and low long-term growth (LTG) estimate for a period of 3 to 5 years for both earnings and sales are $23 and $14 respectively.

Abbott Laboratories (ABT) has a mean revenue estimate for the ongoing quarter ending Dec 16 of $5.41B, according to 12 analysts. Braver Wealth Mgmt Ltd Liability Com has 0.08% invested in the company for 6,000 shares. Bristol-Myers Squibb's dividend payout ratio (DPR) is presently 87.36%.

Zacks piles analysts' views and finds average to get a score on a beginner's scale.

The current ratio for Bristol-Myers Squibb Company NYSE shows a rate of 1.5 with its quick ratio of 1.3. The rating was upgraded by UBS on Tuesday, September 29 to "Buy".

08/10/2016 - Bristol-Myers Squibb Company had its "buy" rating reiterated by analysts at Argus. The company's existing price is 56.55 with a change in volume of 10336500. Stock monthly performance is recorded as 3.56% while its performance in last one week is 1.46%. The rating scale runs from 1 to 5 with 5 indicating a Strong Sell, 1 indicating a Strong Buy and 3 indicating a Hold. The $68.90 average target is 21.09% above today's ($56.9) stock price.

The current assessment for Bristol-Myers Squibb Company NYSE:BMY Drug Manufacturers - Major on its PE ratio displays a value of 28.16 with a Forward PE of 19. In comparison, the consensus recommendation 60 days ago was at 1.82, and 90 days ago was at 2 respectively. Following the sale, the director now directly owns 334,499 shares in the company, valued at $19,022,958.13. The transaction was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. West Coast Fincl Limited Co last reported 0.13% of its portfolio in the stock.

Bristol-Myers Squibb Company is engaged in the discovery, development, licensing, manufacturing, marketing, distribution and sale of biopharmaceutical products. It offers chemically-synthesized drug or small molecule, and biologic in various therapeutic areas, including virology comprising human immunodeficiency virus infection (HIV); oncology; immunoscience; cardiovascular; and neuroscience.